Oncology Review Division At The Head Of The Pack – But Can The Others Keep Up?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Analysis of drug review performance by division finds Cardiovascular & Renal Drugs Division to occupy the lower end of the spectrum. Staffing appears to be a vital component of review performance, giving weight to the researchers’ warning of impending wholesale staff turnover.
You may also be interested in...
BIO Survey Seeks To Uncover Inconsistencies In Review Divisions
The trade group will ask members to characterize their pre-clinical and clinical stage interactions with FDA in an effort to find potential efficiencies as well as inform upcoming legislation, including PDUFA VI.
Lagging CDER Review Divisions Could Learn From Oncology, Antiviral Offices
FDA’s drugs center should identify “best practices” in oncology and antiviral drug reviews that could be applied by less efficient review divisions, such as cardio/renal and neurology, authors of a Manhattan Institute report say.
Are The 90s Back? Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High
With 45 new molecular entities and novel biologics cleared in 2012, FDA approvals have reached a level not seen since the mid-1990s, the golden age of modern medicine. The group reflects a boom in oncology; other drug development trends like orphan diseases and personalized medicine held steady. Big pharma contributed just over a third of the 2012 class, with Pfizer regaining the lead with five novel approvals.